Why the study?
Does the hepatic lipase gene -514 C-->T polymorphism determine angiographic CAD regression in response to intensive lipid-lowering treatment in middle-aged men with dyslipidemia and established CAD?
Population
49 middle-aged men with dyslipidemia and established coronary artery disease (CAD)
Comparison
Intensive lipid-lowering therapy vs Comparison across hepatic lipase gene -514 C-->T…
Design
Cohort
Authors
Loading...
Genotype may predict CAD regression on lipid-lowering therapy; leaves open whether testing improves outcomes in practice.
Does the hepatic lipase gene -514 C-->T polymorphism determine angiographic CAD regression in response to intensive lipid-lowering treatment in middle-aged men with dyslipidemia and established CAD?
The hepatic lipase gene -514 C-->T polymorphism strongly predicts angiographic coronary artery disease regression and favorable lipid changes in response to intensive lipid-lowering therapy.
Zambon et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: